Results 121 to 130 of about 72,813 (290)
This system adopts a biomimetic phospholipid structure, covalently binding iNOS inhibitors, neuroprotective agent PCA and vitamin E derivatives through pH/ROS dual‐responsive bonds, and assembles them with Prussian blue nanozyme to form PBB@AHA. It can efficiently penetrate the blood‐brain barrier and simultaneously release multiple active components ...
Mengcheng Guo +9 more
wiley +1 more source
Clearance of an intravenous iohexol dose of 3235 mg is used to assess glomerular filtration rate (GFR), although systematic assessment of its pharmacokinetic (PK) properties is incomplete.
Qian Dong +8 more
doaj +1 more source
Combating VEGFA‐siRNA‐Induced Metabolic Reprogramming via Glucose Utilization Deprivation
An ionizable lipid nanoparticle co‐delivers VEGFA siRNA and glucose oxidase to tumors to counteract VEGFA knockdown‐induced, glutamine‐driven metabolic compensation. Enzymatic glucose consumption reverses the adaptive pathways and restores metabolism toward baseline, thereby sensitizing tumors to therapy.
Lulu Zheng +10 more
wiley +1 more source
Sex‐Specific Regulation of Glycemic Homeostasis by Theabrownin from Pu‐erh Tea
Pu‐erh tea's key component, theabrownin (TB), lowers blood glucose in a sex‐specific manner. In females, estrogen boosts intestinal MUC2 production, which dramatically enhances TB's ability to inhibit the carbohydrate‐digesting enzyme α‐glucosidase.
Yang Li +22 more
wiley +1 more source
Fluorescent BODIPY‐conjugated thiosemicarbazone ligands and their Ga(III), In(III), and Fe(III) complexes, inspired by Triapine, are developed as theranostic agents. Multiphoton FLIM and confocal microscopy in cancer cells and zebrafish reveal real‐time uptake, mitochondrial localisation, and whilst spectroscopic assays indicated preserved complex ...
Megan J. Green +15 more
wiley +1 more source
Innovative Approaches to Optimize Clinical Transporter Drug–Drug Interaction Studies
Of the 450 cell membrane transporters responsible for shuttling substrates, nutrients, hormones, neurotransmitters, antioxidants, and signaling molecules, approximately nine are associated with clinically relevant drug–drug interactions (DDIs) due to ...
Sabina Paglialunga +2 more
doaj +1 more source
T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu +7 more
wiley +1 more source
We developed an implantable dual‐drug depot using GelMA for bone metastasis treatment, co‐delivering MSA‐2 and αB7‐H3‐loaded CaCO3 microparticles. Sustained release from GelMA scaffold enables MSA‐2 to activate STING signaling and enhance T‐cell infiltration and activation, while sequentially released αB7‐H3 blocks MSA‐2‐induced B7‐H3 upregulation ...
Qijun Lin +10 more
wiley +1 more source
Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor used in first-line combination antiretroviral therapy (cART). It is usually administered with nucleoside reverse transcriptase inhibitors (NRTI), many of which are substrates of OCT ...
Martina Ceckova +4 more
doaj +1 more source
Integrating Spatial Proteogenomics in Cancer Research
Xx xx. ABSTRACT Background: Spatial proteogenomics marks a paradigm shift in oncology by integrating molecular analysis with spatial information from both spatial proteomics and other data modalities (e.g., spatial transcriptomics), thereby unveiling tumor heterogeneity and dynamic changes in the microenvironment.
Yida Wang +13 more
wiley +1 more source

